Delving into the Latest Updates on Durata Therapeutics International BV with Synapse

A phase 3, multicenter, open-label, randomized, comparatorcontrolled trial of the safety and efficacy of Dalbavancinversus Active Comparator in pediatric subjects with AcuteBacterial Skin and Skin Structure Infections

开始日期2016-10-31

申办/合作机构

ASSOCIACAO HOSPITALAR DE PROT INFANCIA DR RAUL CARNEIRO

[+1]

NCT02344511

/ Withdrawn临床3期

A Phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be Due to Gram-Positive Organisms

Dalbavancin for Pediatric Osteomyelitis

开始日期2016-03-01

申办/合作机构

Durata Therapeutics International BV

EUCTR2014-000419-15-HR

/ Not yet recruitingN/A

A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

开始日期2014-10-31

申办/合作机构

Durata Therapeutics International BV

100 项与 Durata Therapeutics International BV 相关的临床结果

登录后查看更多信息

0 项与 Durata Therapeutics International BV 相关的专利（医药）

登录后查看更多信息

100 项与 Durata Therapeutics International BV 相关的药物交易

登录后查看更多信息

100 项与 Durata Therapeutics International BV 相关的转化医学

登录后查看更多信息